A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Jazz Pharmaceuticals
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Fudan University
Taiho Oncology, Inc.
Hoffmann-La Roche
Hoffmann-La Roche
Peking University Cancer Hospital & Institute
Peking University Cancer Hospital & Institute
Jazz Pharmaceuticals
Merck Sharp & Dohme LLC
Fujian Cancer Hospital
Sun Yat-sen University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Eurofarma Laboratorios S.A.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Merck Sharp & Dohme LLC
Taiho Pharmaceutical Co., Ltd.
University of Oxford
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Samsung Medical Center
Tianjin Medical University Cancer Institute and Hospital
Sun Yat-sen University
Merck Sharp & Dohme LLC
Nanfang Hospital, Southern Medical University
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
The First Affiliated Hospital with Nanjing Medical University
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Cancer Trials Ireland
Tianjin Medical University Cancer Institute and Hospital
Boston Scientific Corporation
Radiation Therapy Oncology Group
Fujian Cancer Hospital
Alliance for Clinical Trials in Oncology
Jiangsu HengRui Medicine Co., Ltd.
Henan Cancer Hospital
AIO-Studien-gGmbH
Sun Yat-sen University
UNICANCER
National Cancer Institute (NCI)
Swiss Cancer Institute
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
ChineseAMS
Federation Francophone de Cancerologie Digestive
University Hospital Schleswig-Holstein
Brown University